CAL
MYGN icon

Capital Advisors Ltd’s Myriad Genetics MYGN Stock Holding History

Capital Advisors Ltd’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+5
New +$23 ﹤0.01% 1503

Other funds holding MYGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
ICP
Impact Capital Partners Greenwood Village, Colorado $367M AUM 28.36% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Capital Advisors Ltd's MYGN Position: Q2 2026 in Review

Capital Advisors Ltd opened a new position in Myriad Genetics (MYGN) in Q2 2026: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1503 among its holdings.

17 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Capital Advisors Ltd held 5 shares of Myriad Genetics worth $0 as of Q2 2026.
  • Myriad Genetics was a new Capital Advisors Ltd position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1503 holding.
  • 17 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.